Document Detail

Comparison of doxorubicin cardiotoxicity in pediatric sarcoma patients when given with dexrazoxane versus as continuous infusion.
MedLine Citation:
PMID:  20795769     Owner:  NLM     Status:  In-Process    
Doxorubicin is an effective agent for many malignancies. To limit cardiotoxicity, doxorubicin can be given as prolonged infusion (PIDX) or bolus infusion following dexrazoxane (DZX). The authors report their institutional experience comparing PIDX and DZX in a sarcoma cohort. Retrospective record review for newly diagnosed sarcoma patients at the University of Texas M.D. Anderson Cancer Center from June 1998 to June 2006. There were 23 Ewing's sarcoma (EWS) patients treated with DZX and 40 osteosarcoma (OS) patients treated with PIDX. The DZX group had higher mean cumulative anthracycline dose (510 mg/m(2) [SD 120 mg/m(2)] versus 414 mg/m(2) [SD 99 mg/m(2)], P = .002), however mean lowest left ventricular ejection fraction (EF) values were higher for DZX (52.5% [SD 5.6%] versus 47.2% [SD 10.9%], P = .014). Fifteen of 19 patients with cardiac dysfunction were PIDX patients (P = .15). Five PIDX patients required cardiac medication, and 1 patient died of congestive heart failure (CHF). Sixteen patients with cardiac dysfunction had improvement, demonstrated by EF ≥ 50% at last echocardiogram. Although not statistically significant, there were 4 DZX patients with cardiac dysfunction. Prospective studies are required to determine which strategy has long-term advantages and if certain patients are at increased risk for cardiac dysfunction.
Winston W Huh; Norman Jaffe; Jean-Bernard Durand; Mark F Munsell; Cynthia E Herzog
Related Documents :
11373489 - Successful extracorporeal life support in a case of severe flecainide intoxication.
2305319 - Clinical diagnosis of cardiac beriberi.
8872289 - Supervised exercise and electrocardiographic monitoring during cardiac rehabilitation. ...
20926019 - Impact of modified treatment in echocardiographically confirmed pseudo-pulseless electr...
9875769 - Cardiac operations in the elderly: who is at risk?
426399 - Whole body hyperthermia: a phase-i trial of a potential adjuvant to chemotherapy.
18691349 - Immunogenicity negatively influences the outcome of adalimumab treatment in crohn's dis...
18404069 - Massive transfusion in trauma patients: tissue hemoglobin oxygen saturation predicts po...
21178289 - Comparison of qt/rr relation based on a 15-s averaged ecg and a single beat ecg during ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Pediatric hematology and oncology     Volume:  27     ISSN:  1521-0669     ISO Abbreviation:  Pediatr Hematol Oncol     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-09-24     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8700164     Medline TA:  Pediatr Hematol Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  546-57     Citation Subset:  IM    
Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Frequency of pulmonary hypertension in asymptomatic ?-thalassemia major patients and the role of phy...
Next Document:  Causes for hospitalization and death in Iranian patients with ?-Thalassemia major.